Theratechnologies’ (THERF) “Hold” Rating Reaffirmed at Mackie

Theratechnologies (OTCMKTS:THERF)‘s stock had its “hold” rating reaffirmed by equities researchers at Mackie in a report released on Wednesday, TipRanks reports.

Separately, ValuEngine upgraded Theratechnologies from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Shares of OTCMKTS THERF traded up $0.17 during midday trading on Wednesday, hitting $3.80. The stock had a trading volume of 133,700 shares, compared to its average volume of 25,677. Theratechnologies has a 1-year low of $3.58 and a 1-year high of $7.29. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.19 and a current ratio of 2.69. The company has a fifty day moving average price of $4.05 and a 200 day moving average price of $4.73.

Theratechnologies (OTCMKTS:THERF) last announced its earnings results on Thursday, July 11th. The company reported ($0.04) EPS for the quarter. The company had revenue of $15.61 million for the quarter. Theratechnologies had a negative net margin of 11.57% and a negative return on equity of 14.31%.

Theratechnologies Company Profile

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.

Read More: What factors cause inflation to rise?

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.